Yaras, S. Et Al. 2023. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort. Hepatology Forum , vol.4, no.3 , 92-96.

Yaras, S., Demir, M., Barutcu, S., Yildirim, A. E., GÜREL, S., Ucbilek, E., ... Kurtulmus, I. A.(2023). The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort. Hepatology Forum , vol.4, no.3, 92-96.

Yaras, Serkan Et Al. "The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort," Hepatology Forum , vol.4, no.3, 92-96, 2023

Yaras, Serkan Et Al. "The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort." Hepatology Forum , vol.4, no.3, pp.92-96, 2023

Yaras, S. Et Al. (2023) . "The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort." Hepatology Forum , vol.4, no.3, pp.92-96.

@article{article, author={Serkan Yaras Et Al. }, title={The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort}, journal={Hepatology Forum}, year=2023, pages={92-96} }